Abstracts Archive - Page 782 of 2607 - ACR Meeting Abstracts

Abstract Number: 1153 • ACR Convergence 2021
The Influence of Companions on a Patient’s Decision to Transition to a Biosimilar: A Randomized Controlled Trial
Chiara Gasteiger¹, Katie Groom¹, Maria Lobo², Urte Scholz³, Keith Petrie¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland District Health Board, Auckland, New Zealand, ³University of Zurich, Zurich, Switzerland
Background/Purpose: Involving patients in treatment decisions is commonplace in healthcare, but patients are frequently accompanied by a support person (companion). Companions are often actively involved…
Abstract Number: 1154 • ACR Convergence 2021
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
Abstract Number: 1155 • ACR Convergence 2021
Pregnancy Experiences and Unmet Needs for Women of Childbearing Age with Chronic Rheumatic Disease in China
xinping tian¹ and yongfei fang², ¹Peking Union Medical College Hospital, beijing, China (People's Republic), ²The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, China (People's Republic)
Background/Purpose: Recent European research on patients with chronic rheumatic diseases (CRDs) revealed that women of childbearing age (WoCBA) have many fears and misconceptions about their…
Abstract Number: 1156 • ACR Convergence 2021
Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
Jessica Walsh¹, Kelley Myers², Carol Mansfield², William Tillett³, Peter Nash⁴, Colton Leach², William Nowell⁵, Kelly Gavigan⁵, Patrick Zueger⁶, Erin McDearmon-Blondell⁷ and Alexis Ogdie-Beatty⁸, ¹Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ²RTI Health Solutions, Research Triangle Park, NC, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Griffith University, Brisbane, Australia, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶AbbVie Inc., Mettawa, IL, ⁷AbbVie Inc., Elmhurst, IL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: To optimize patient-provider shared decision-making, it is important to understand patients’ experience with psoriatic arthritis (PsA) and its treatment, including how treatment experience may…
Abstract Number: 1157 • ACR Convergence 2021
Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
David Vega Morales¹, Alejandro Garza-Alpirez² and Carlos Andrés Díaz-Garza², ¹Hospital Universitario, Garcia, Mexico, ²Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, San Pedro, Mexico
Background/Purpose: The use of biosimilars instead of its originator is a controversial subject with many implications. It is considered that a non medical switch should…
Abstract Number: 1158 • ACR Convergence 2021
Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Kaleb Michaud¹, Sofia Pedro², Victoria Jasion³, Holly Budlong⁴, Jessica Suboticki⁵, Frederick Wolfe⁶ and Patricia Katz⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³AbbVie, Overland Park, KS, ⁴AbbVie, Minneapolis, MN, ⁵AbbVie Inc., North Chicago, IL, ⁶National Data Bank for Rheumatic Diseases, Wichita, KS, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness…
Abstract Number: 1159 • ACR Convergence 2021
Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions
Courtney Wells¹, Peter Chira², Dana Guglielmo³, Stacy Ardoin⁴, Katelyn Melcher⁵, Meghan Trimble⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Pediatric Rheumatology, University of California San Diego, Rady Children’s Hospital, San Diego, CA, ³Student, Atlanta, GA, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Patient Partner, Ankeny, IA, ⁶Patient Partner, Minneapolis, MN, ⁷Independent, San Diego, CA
Background/Purpose: Implementation of structured healthcare transition processes remains elusive for most US rheumatology clinics (Johnson et al., 2021). Although research studies have proposed models and…
Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Diana Meyler¹, Sofia Pedro², Alan Erickson³, Patricia Katz⁴ and Kaleb Michaud³, ¹UNMC, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1162 • ACR Convergence 2021
Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
Jackie Tsang¹, Orli Silverberg¹, Rohan Machhar², Remy Pollock³, Mitchell Sutton⁴, Daniel Pereira³, Dafna Gladman⁵ and Cheryl Rosen¹, ¹University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: We aimed to assess the correlation between cannabis use and psoriatic disease severity, health-related quality of life, pain, and psychosocial outcomes in psoriasis without…
Abstract Number: 1163 • ACR Convergence 2021
Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
Shivani Garg¹, Betty Chewning¹, Noah Kaitz¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
Abstract Number: 1164 • ACR Convergence 2021
A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Alan Zhou, Nancy Maltez and Catherine Ivory, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Intravenous Immunoglobulin (IVIg) is used to treat rheumatic conditions such as Inflammatory Myositis. Subcutaneous Immunoglobulin (SCIg) is an alternative route of administering Immunoglobulin. Studies…
Abstract Number: 1165 • ACR Convergence 2021
“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
Philip Mease¹, Dan Furst², Evan Siegel³, Vibeke Strand⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Arthritis and Rheumatism Associates, Potomac, MD, ⁴Stanford University School of Medicine, Portola Valley, CA, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Recent psoriatic arthritis (PsA) treatment recommendations (1), highlight the importance of shared decision making; this ideally requires the clinician understands “what matters” to each…
Abstract Number: 1166 • ACR Convergence 2021
Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe
Rebecca Fitzpatrick¹, Najia Shakoor², Michael Grant² and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: With the legalization of marijuana in many states, rheumatologists are having increased inquiries from patients regarding marijuana use in addition to their pain regimen.…
Abstract Number: 1167 • ACR Convergence 2021
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Kelly O'Neill¹, Pamela Sinicrope², Kathryne Marks³, Elena Myasoedova², Cynthia Crowson⁴ and John Davis², ¹Rheumatoid Patient Foundation, Lutz, FL, ²Mayo Clinic, Rochester, MN, ³Rheumatoid Patient Foundation, Boston, MA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Shared decision making and treat to target are recognized guidelines to treat Rheumatoid Arthritis (RA). We previously reported associations of shared treatment goal discussions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].